Grifols SA (GRF):企業の財務・戦略的SWOT分析

◆英語タイトル:Grifols SA (GRF) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1678
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:72
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スペイン
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Grifols SA (GRF) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Grifols SA (Grifols) focuses on improving the health and well-being of people around the world. It conducts research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. It produces plasma derived protein therapies for patients suffering with rare, chronic and life-threatening infections. Grifols offers biological materials for clinical trials, biotechnology research, manufacturing pharmaceutical and diagnostic products. The company has plasma donation centers across the US. Grifols provides transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. The company offers products to hospitals, pharmacies and healthcare professionals. Grifols is headquartered in Barcelona, Spain.

Grifols SA Key Recent Developments

Mar 27,2020 Grifols and Shanghai RAAS close their strategic alliance in China
Mar 26,2020 Grifols teams up with US to test plasma therapy for Covid-19
Mar 25,2020 Grifols announces formal collaboration with US Government to produce the first treatment specifically targeting COVID-19
Feb 27,2020 Grifols reaches revenue of EUR 5,100 million, a 13.6% increase, and raises its profits to EUR 625 million

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Grifols SA – Key Facts
Grifols SA – Key Employees
Grifols SA – Key Employee Biographies
Grifols SA – Major Products and Services
Grifols SA – History
Grifols SA – Company Statement
Grifols SA – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Grifols SA – Business Description
Business Segment: Bio Supplies
Overview
Performance
Business Segment: Bioscience
Overview
Performance
Key Stats
Business Segment: Diagnostic
Overview
Performance
Key Stats
Business Segment: Hospital
Overview
Performance
Business Segment: Others
Overview
Performance
Geographical Segment: European Union
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: Spain
Performance
Geographical Segment: USA and Canada
Performance
R&D Overview
Grifols SA – SWOT Analysis
SWOT Analysis – Overview
Grifols SA – Strengths
Grifols SA – Weaknesses
Grifols SA – Opportunities
Grifols SA – Threats
Grifols SA – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences, Power Financial Deals and Alliances
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Grifols SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Grifols SA, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 27, 2020: Grifols and Shanghai RAAS close their strategic alliance in China
Mar 26, 2020: Grifols teams up with US to test plasma therapy for Covid-19
Mar 25, 2020: Grifols announces formal collaboration with US Government to produce the first treatment specifically targeting COVID-19
Feb 27, 2020: Grifols reaches revenue of EUR 5,100 million, a 13.6% increase, and raises its profits to EUR 625 million
Feb 13, 2020: Grifols PharmacyKeeper ranked No. 1 in KLAS rating, extends category leadership
Dec 05, 2019: Grifols streamlines Hospital Pharmacy operations with new KIRO Fill technology and PharmacyKeeper enhancements
Jul 31, 2019: Grifols increases its revenues by 14.3% to EUR 2,423 million, driven by its strategic growth plan
Jul 03, 2019: Grifols selected to build its first intravenous solutions manufacturing line in Africa
May 24, 2019: Grifols reinforces its long-term and sustainable growth strategy with EUR 1,400 million in capital investments in 2018-2022
May 08, 2019: Grifols reports 13% revenue growth to EUR 1,157 million and confirms its solid operational performance
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Grifols SA, Key Facts
Grifols SA, Key Employees
Grifols SA, Key Employee Biographies
Grifols SA, Major Products and Services
Grifols SA, History
Grifols SA, Other Locations
Grifols SA, Subsidiaries
Grifols SA, Key Competitors
Grifols SA, Ratios based on current share price
Grifols SA, Annual Ratios
Grifols SA, Annual Ratios (Cont...1)
Grifols SA, Annual Ratios (Cont...2)
Grifols SA, Interim Ratios
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Grifols SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Grifols SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Grifols SA, Performance Chart (2015 - 2019)
Grifols SA, Ratio Charts
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Grifols SA, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Grifols SA (GRF):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Exelon Corp (EXC):企業の財務・戦略的SWOT分析
    Exelon Corp (EXC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Cadila Healthcare Ltd (CADILAHC):企業の財務・戦略的SWOT分析
    Cadila Healthcare Ltd (CADILAHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Daicel Corp (4202)
    Daicel Corp (4202) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • QCR Holdings, Inc.:企業のM&A・事業提携・投資動向
    QCR Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's QCR Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Shri Lakshmi Cotsyn Ltd.:企業の戦略・SWOT・財務情報
    Shri Lakshmi Cotsyn Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shri Lakshmi Cotsyn Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • NII Holdings Inc (NIHD):企業の財務・戦略的SWOT分析
    Summary NII Holdings Inc (NII Holdings) is a mobile communication service provider that offers communication products and services. The company offers solutions such as 3G mobile broadband services, content downloads and messaging. It also provides digital cellular voice services, data services, and …
  • British American Tobacco p.l.c.:企業の戦略・SWOT・財務情報
    British American Tobacco p.l.c. - Strategy, SWOT and Corporate Finance Report Summary British American Tobacco p.l.c. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • OSANG Healthcare Co Ltd (036220):製品パイプライン分析
    Summary OSANG Healthcare Co Ltd (OSANG), formerly Infopia Co Ltd is a medical device company that designs, develops and distributes diagnostic biosensors for heart disease and cancers and remote diagnosing systems. The company offers diagnostic biosensors for blood glucose, hemoglobin A1c, cholester …
  • Aerosup Inc.:企業の戦略・SWOT・財務分析
    Aerosup Inc. - Strategy, SWOT and Corporate Finance Report Summary Aerosup Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Lechwerke AG (LEC):企業の財務・戦略的SWOT分析
    Summary Lechwerke AG (LechWerke), a subsidiary of Innogy SE is a utility service provider that offers electricity products natural gas products and energy services. The company provides services such as electrical safety, gas safety, energy monitoring, power plant contracting, street lighting, energ …
  • Northstar Aerospace Inc.:企業の戦略・SWOT・財務情報
    Northstar Aerospace Inc. - Strategy, SWOT and Corporate Finance Report Summary Northstar Aerospace Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Aura Light International AB:企業の戦略的SWOT分析
    Aura Light International AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Nanosphere Inc-医療機器分野:企業M&A・提携分析
    Summary Nanosphere Inc (Nanosphere) a subsidiary of Cepheid is a medical device company that develops molecular diagnostic tests for disease detection and patient treatment. The company’s products comprise verigene system, instrumentation, bloodstream infection tests, gastrointestinal infection test …
  • Natural Beauty Bio-Technology Ltd.:戦略・SWOT・企業財務分析
    Natural Beauty Bio-Technology Ltd. - Strategy, SWOT and Corporate Finance Report Summary Natural Beauty Bio-Technology Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Uni-President Enterprises Corp:企業の戦略・SWOT・財務情報
    Uni-President Enterprises Corp - Strategy, SWOT and Corporate Finance Report Summary Uni-President Enterprises Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Oswaldo Cruz Foundation:製薬・医療:M&Aディール及び事業提携情報
    Summary Oswaldo Cruz Foundation (Oswaldo Cruz) is a provider of research and development in biological sciences. It offers research programs and technological development projects in vaccines production, medications, drugs, reagents and diagnostic kits. The foundation provides research in experiment …
  • Neurosigma Inc:企業の製品パイプライン分析2018
    Summary Neurosigma Inc (Neurosigma) is a life science company that develops and commercializes trigeminal nerve stimulation technologies for neurologic and psychiatric disorders. The company offers treatments for epilepsy, depression, attention deficit hyperactivity disorder, and post-traumatic stre …
  • Flowserve Corp (FLS):企業の財務・戦略的SWOT分析
    Flowserve Corp (FLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Main Street America Group Inc:企業の戦略的SWOT分析
    Main Street America Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • UCL Business PLC:企業のM&A・事業提携・投資動向
    UCL Business PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's UCL Business PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆